Safety and Tolerability

Safety & Tolerability

The gastrointestinal (GI) side effects associated with oral iron therapy can be an unwelcome accompaniment to treatment for iron deficiency anemia. Ferralet® 90 with Ferr-Ease®* has been created to make iron therapy as gentle and comfortable as possible while adding to the patient’s vital iron stores.

The Ferralet 90 formulation contains a small amount of ferrous gluconate, with a lower elemental iron content, for rapid absorption.

The absorption of carbonyl iron is dependent upon the patient’s own production of gastric acid, which determines the rate of conversion from the particulate to the soluble ionized form. As a result, carbonyl iron is absorbed in a more prolonged process that has demonstrated excellent tolerability and safety.1 In fact, in a large, randomized, double-blind trial, carbonyl iron dosed at 600 mg was tolerated with gastrointestinal side effects similar to those observed with a 60 mg dose of ferrous sulfate.2

Ferralet 90 also contains 50 mg docusate sodium, a gentle and effective stool softener that helps prevent the constipation that might occur in patients sensitive to iron therapy.

* US Patent no. 6,521,247

1 Shah A. Iron deficiency anemia—Part III. Indian J Med Sci. 2004;58(5):214-216.

2 Gordeuk VR, Brittenham GM, Hughes M, Keating LJ, Opplt JJ. High-dose carbonyl iron for iron deficiency anemia: a randomized double-blind trial. Am J Clin Nutr. 1987;46(6):1029-1034.